top of page
  • Writer's pictureEscalate Life Sciences

Tandem Diabetes Launches a New Version of Its Insulin Pump

New software technology will make its insulin pumps even more effective.


Tandem Diabetes (NASDAQ:TNDM) today announced the commercial launch of the newest version of its flagship insulin pump in the U.S. market. The company's signature t:slim X2 insulin pump will also now come with Control-IQ technology, which is meant to help stabilize blood sugar levels via an automated insulin dosing system.

Insulin pumps are a type of insulin delivery device that simulate the way the pancreas works by delivering small doses of insulin throughout the body. Tandem's main product is its t:slim X2 pump, one of the top insulin pumps in the market right now, with sales having seen dramatic growth over the past couple of years.

"Control-IQ technology has been described by study participants and investigators as 'life-changing,' 'easy to use,' and 'a new standard of care in insulin therapy management'," said Tandem CEO John Sheridan. This technology, which will be made available to existing t:slim users via a software update, is only compatible with one other insulin monitoring system out there, Dexcom's G6 continuous glucose monitoring tool (the G6, however, is not an insulin pump). 

Written by: Mark Prvulovic (TMFmarkprvulovic)

Published on: Jan 15, 2020 at 6:25PM


7 views0 comments
bottom of page